PCSK9 and Alzheimer disease: In particular, counteracting systemic PCSK9, blood cholesterol levels and inflammatory/oxidative events that contribute to BBB injury could be reduced; for this reason, the systemic PCSK9 targeting could be suggested for AD prevention or treatment during the early prodromal phases, while neutralizing brain PCSK9 could be helpful in delaying full-blown AD progression.